Login
$ABCL
$11.19 +$0.07 (0.63%) After hours

$ABCL SEC Filings

Filed On Filing
16 Nov 2026 Form 4: Booth Andrew, Chief Financial Officer

Received 50,000 shares by exercise or conversion ($16.1K) · Gave 50,000 shares as a gift

13 Nov 2026 Form 4: Thermopylae Holdings Ltd., 10% owner

Gave 125,000 shares as a gift

13 Nov 2026 SCHEDULE 13G/A
13 Nov 2026 Form 4: Booth Andrew, Chief Financial Officer

Bought 8,600 shares ($97.4K)

12 Nov 2026 Form 4: Thermopylae Holdings Ltd., 10% owner

Bought 60,565 shares ($699K)

09 Nov 2026 10-Q
09 Nov 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the third quarter of 2026. All financial information in this press release is reported in U.S. dollars, unless otherwise indica...

24 Aug 2026 Form 4: Hayden Michael R, Director

Bought 53,613 shares ($570K)

18 Aug 2026 Form 4: Montalbano John S., Director

Bought 10,000 shares ($110K)

14 Aug 2026 Form 4: Booth Andrew, Chief Financial Officer

Bought 37,200 shares ($384K)

14 Aug 2026 Form 4: Hayden Michael R, Director

Bought 46,387 shares ($481K)

13 Aug 2026 8-K: Entry into a Material Definitive Agreement; Other Events

Introductory. AbCellera Biologics Inc., a corporation incorporated under the Business Corporations Act (British Columbia) (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A (the “Underwriters”) (i...

13 Aug 2026 424B5
13 Aug 2026 Form 4: Hayden Michael R, Director

Gave 50,000 shares as a gift

11 Aug 2026 424B5
10 Aug 2026 8-K: Regulation FD Disclosure

These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking...

07 Aug 2026 8-K: Other Events

150 W 4th Ave Vancouver, BC V5Y 1G6 T 1. 604.559.9005 abcellera.com NEWS RELEASE AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to- Severe VMS Due to Menopause on Monday, August 10,...

05 Aug 2026 10-Q
05 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced financial results for the second quarter of 2026. All financial information in this press release is reported in U.S. dollars, unless otherwise indic...

29 Jul 2026 8-K: Other Events

150 W 4th Ave Vancouver, BC V5Y 1G6 T 1. 604.559.9005 abcellera.com NEWS RELEASE AbCellera Announces Collaboration with Vertex to Discover Multispeci�c T-Cell Engagers for Autoimmune Diseases and Other Conditions 2026-07-29 VANCOUVER, Br...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support